homeimg-adj

 

KOL conversations move fast.
KOL Pulse AI helps you keep up.

KOL Pulse AI is leading the way in Oncology KOL Discussion tracking.

Cut through the social media noise, get right to the KOL insights using our tool.

Turn KOL Activity into Actionable Intelligence

  • Track oncology breakthroughs discussed by the most respected Key Opinion Leaders (KOLs) on social media
  • Follow real-time KOL sentiment on emerging treatments, controversies, and trends
  • Discover true peer influence based on social engagement scores and peer interactions, not just follower counts
  • Get transparency with built-in Open Payments data showing financial conflicts of interest
  • Exclusively track US based oncologists in global oncology conversations
  • Leverage AI-powered analysis to filter, rank, and surface key discussions
  • Install the free Chrome Extension for enhanced X timeline insights and KOL transparency

Want to see what the experts are saying? Download the KOL Pulse AI Chrome Extension

Top Trending KOLs

October 2025

  • Myeloma
  • GU Cancer
# KOL Influence Overview
1
banerjee

Dr. Rahul Banerjee

Fred Hutch Cancer Center
Dr. Banerjee was the top influencer at #IMS25 sharing content from his peers in real-time and engaging in discussions with many of his other myeloma expert colleagues.
2
Dr. Saad Usmani

Dr. Saad Usmani

MD Anderson Cancer Center
Dr. Usmani's presentation at IMS25 on the ability to cure multiple myeloma in the next 10 years was a trending discussion among the Myeloma KOL community.
3
sameralhadidiround

Dr. Samer Al Hadidi

UTSW Simmons Cancer Center
Popular Tweet is a grand rounds presentation on Current Perspectives in the Management of Smoldering Multiple Myeloma
# KOL Influence Overview
1
plimmack

Dr. Elizabeth Plimack

Fox Chase Cancer Center

No overview available

Lung Cancer Top Trending Slides

October 2025

Dr. Stephen V Liu
Dr. Stephen V Liu
Dr. Stephen V Liu
Lombardi Comprehensive Cancer Center and Georgetown University

Dr. @APassaroMD with a great overview of next-line therapy for EGFR NSCLC at #BTGGlobalLung2025. Rapid changes emerging and anticipate impact with ADCs. Will be influenced by first-line therapy. More and more, resistance seems to be multifaceted, overlapping mechanisms.

View Post

Jill Feldman
Jill Feldman
Jill Feldman
Lung Cancer Patient and Advocate

Fantastic, thoughtful discussion between @OncBrothers & @lungoncdoc about 1st line treatment options for #EGFR #NSCLC. Having options that have significant OS benefits is amazing, but all regimens have toxicities.

Every lung #onc should not just prescribe treatment, but also lean into supportive regimens to help people live better and stay on treatment.

Thanks for the callout. A reduction in side effects is important for clinical management, but the #QOL data, reported by the patients, that I presented at ASCO, is what matters.

View Full Post

Dr. Stephen V Liu
Dr. Stephen V Liu
Dr. Stephen V Liu
Lombardi Comprehensive Cancer Center and Georgetown University
Dr. Pedro Rocha at #ESMO25 shows subset data from DeLLphi-304 (2L tarlatamab vs chemo in SCLC). If CTFI <90d (platinum resistant), OS HR 0.60 and if CTFI ≥90d, mOS 17.1 vs 10.6m, HR 0.65. If prior PDL1 given, OS HR 0.61, if not given, OS HR 0.65.
Dr. Antonio Calles
Dr. Antonio Calles
Dr. Antonio Calles
Hospital General Universitario Gregorio Marañón and Ruber Internacional
Tarlatamab incorporated upfront with chemo-immunotherapy breaks all the known stats in first-line SCLC. No new data safety concerns. Awaiting data from randomized ph3 trial, but likely to be the next SoC.
 

Breast Cancer Top Trending Slides

October 2025

Dr. Erika Hamilton
Dr. Erika Hamilton
Dr. Erika Hamilton
Director of Breast Cancer Research Program at Sarah Cannon Research Institute
@elmayermd presents #SERENA6 QoL data #ESMO25 - switch to cami/CDK at emergence of ESR1m in ABSENCE of PD vs. staying on AI/CDK 
 
TTD in pain, SOB, fatigue, arm symptoms, physical fxn, etc. lengthened with early switch therapy
 
 
Dr. Matteo Lambertini
Dr. Matteo Lambertini
Dr. Matteo Lambertini
Ospedale San Martino Genova

More data from #DestinyBreast09 presented at #ESMO25 supporting the combination of #TDXd plus #pertuzumab as preferred first-line therapy in patients with #HER2+ advanced #BreastCancer

Dr. Rishabh Jain
Dr. Rishabh Jain
Dr. Rishabh Jain
AIIMS Delhi

Dato-DXd doubles ORR & improves survival in 1L TNBC!

#TROPIONBreast02 | Phase III | 1L inoperable/metastatic TNBC 

Arms: 

Dato-DXd 6 mg/kg Q3W (n=323) 
Investigator’s choice chemo (ICC, n=321) 

Results (BICR):

ORR: 62.5% vs 29.3% (Δ +33%)
CR: 9% vs 2.5%
Median PFS: 10.8 mo vs 5.6 mo (HR 0.57) Median OS: 23.7 mo vs 18.7 mo (HR 0.79) 

Takeaway: Dato-DXd significantly improved PFS (+5.3 mo) and OS (+5.0 mo) vs chemo

#ESMO25 #OncoTwitter #BreastCancer #TNBC

@AnnOncology

View Post

Dr. Matteo Lambertini
Dr. Matteo Lambertini
Dr. Matteo Lambertini
Ospedale San Martino Genova
First-line therapy in patients with advanced triple-negative #PDL1- (or IO ineligible) will change after #ESMO25: great presentation by super @JavierCortesMD of the #ASCENT03 trial #sacituzumabGovitecan
 

Multiple Myeloma Top Trending Slides

October 2025

Dr. Stephen V Liu
Dr. Stephen V Liu
Dr. Stephen V Liu
Lombardi Comprehensive Cancer Center

Dr. @APassaroMD with a great overview of next-line therapy for EGFR NSCLC at #BTGGlobalLung2025. Rapid changes emerging and anticipate impact with ADCs. Will be influenced by first-line therapy. More and more, resistance seems to be multifaceted, overlapping mechanisms.

View Post

Dr. Stephen V Liu
Dr. Stephen V Liu
Dr. Stephen V Liu
Lombardi Comprehensive Cancer Center

Dr. Pedro Rocha at #ESMO25 shows subset data from DeLLphi-304 (2L tarlatamab vs chemo in SCLC). If CTFI <90d (platinum resistant), OS HR 0.60 and if CTFI ≥90d, mOS 17.1 vs 10.6m, HR 0.65. If prior PDL1 given, OS HR 0.61, if not given, OS HR 0.65.

 #ESMOAmbassadors

View Post

Dr. Hamza Hashmi
Dr. Hamza Hashmi
Dr. Hamza Hashmi
Memorial Sloan Cancer Center

MRD vs No MRD guided treatment for Myeloma: A great debate b/w @szusmani (yes) vs @End_myeloma (no) and discussion by @VincentRK on MRD driven treatment in Multiple Myeloma Kyle Barlogie Plasma Cell Disorders Symposium #MMSM #MedTwitter #MedEd #AgreeToAgree

View Post

Dr. Akiko Chiba
Dr. Akiko Chiba
Dr. Akiko Chiba
Duke Health
Excellent overview of screening after breast cancer ⁦@AnnaWeissMD

Annual mammo after BCS (no utility of more frequent imaging)

Supplemental MR for high risk

No routine screening after mastectomy
 
 
Dr. Stephen V Liu
Dr. Stephen V Liu
Dr. Stephen V Liu
Lombardi Comprehensive Cancer Center

Dr. Pedro Rocha at #ESMO25 shows subset data from DeLLphi-304 (2L tarlatamab vs chemo in SCLC). If CTFI <90d (platinum resistant), OS HR 0.60 and if CTFI ≥90d, mOS 17.1 vs 10.6m, HR 0.65. If prior PDL1 given, OS HR 0.61, if not given, OS HR 0.65.

 #ESMOAmbassadors

View Post